MiRNA-223-3p Affects Mantle Cell Lymphoma Development by Regulating the CHUK/NF-ƘB2 Signaling Pathway

References

• Velders GA, Kluin-Nelemans JC, De Boer CJ, et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol. 1996;14(4):1269–1274. doi:10.1200/JCO.1996.14.4.1269
   PubMed Web of Science ®Google Scholar
• Gauthier J, Maloney DG. Allogeneic transplantation and chimeric antigen receptor-engineered T-Cell therapy for relapsed or refractory mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34(5):957–970. doi:10.1016/j.hoc.2020.06.010
   PubMed Web of Science ®Google Scholar
• Bond DA, Maddocks KJ. Current role and emerging evidence for bruton tyrosine kinase inhibitors in the treatment of mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34(5):903–921. doi:10.1016/j.hoc.2020.06.007
   PubMed Web of Science ®Google Scholar
• Ruan J. Approach to the initial treatment of older patients with mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34(5):871–885. doi:10.1016/j.hoc.2020.06.005
   PubMed Web of Science ®Google Scholar
• Guy D, Kahl BS. Initial and consolidation therapy for younger patients with mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34(5):861–870. doi:10.1016/j.hoc.2020.06.004
   PubMed Web of Science ®Google Scholar
• Sawalha Y, Bond DA, Alinari L. Evaluating the therapeutic potential of zanubrutinib in the treatment of relapsed/refractory mantle cell lymphoma: evidence to date. Onco Targets Ther. 2020;13:6573–6581. doi:10.2147/OTT.S238832
   PubMed Web of Science ®Google Scholar
• Santambrogio E, Novo M, Rota-Scalabrini D, Vitolo U. Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice. Expert Rev Hematol. 2020;13(8):851–869.
   PubMed Web of Science ®Google Scholar
• Rule S, Johns S. Advances in classification and treatment of non-hodgkin lymphoma: mantle cell. Cancer J. 2020;26(4):348–356. doi:10.1097/PPO.0000000000000462
   PubMed Web of Science ®Google Scholar
• Wang X, Li W, Wang X, et al. The effectiveness and harms of bortezomib in combination with chemotherapy for mantle cell lymphoma: a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020;99(28):e20961. doi:10.1097/MD.0000000000020961
   PubMed Web of Science ®Google Scholar
• Li P, Dong N, Zeng Y, et al. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma. Front Med. 2020;14(6):811–815.
   PubMed Web of Science ®Google Scholar
• Villa D, Sehn LH, Savage KJ, et al. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. Blood Adv. 2020;4(15):3486–3494. doi:10.1182/bloodadvances.2020002068
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi:10.1016/S0092-8674(04)00045-5
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006;66:7390–7394. doi:10.1158/0008-5472.CAN-06-0800
   PubMed Web of Science ®Google Scholar
• Zhou K, Feng X, Wang Y, et al. miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11. Exp Hematol. 2018;58(27–34.e1). doi:10.1016/j.exphem.2017.10.005
   PubMedGoogle Scholar
• Rahal R, Frick M, Romero R, et al. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20(1):87–92. doi:10.1038/nm.3435
   PubMed Web of Science ®Google Scholar
• Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, Liu ZG. MicroRNAs modulate the noncanonical transcription factor NF-κB pathway by regulating expression of the kinase IKKα during macrophage differentiation. Nat Immunol. 2010;11(9):799–805. doi:10.1038/ni.1918
   PubMed Web of Science ®Google Scholar
• Wong WL, Lung WM, Law TY, Lai BS, Wong N. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of stathmin1. Gastroenterology. 2008;135(1):257–269. doi:10.1053/j.gastro.2008.04.003
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342. doi:10.1056/NEJMoa1914347
   PubMed Web of Science ®Google Scholar
• Phillips T, Barr PM, Park SI, et al. A Phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Invest New Drugs. 2019;37(2):297–306. doi:10.1007/s10637-018-0655-0
   PubMed Web of Science ®Google Scholar
• Davids MS, Kim HT, Nicotra A, et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol. 2019;6(1):e38–e47. doi:10.1016/S2352-3026(18)30196-0
   PubMed Web of Science ®Google Scholar
• Gressin R, Daguindau N, Tempescul A, et al. A Phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. Haematologica. 2019;104(1):138–146. doi:10.3324/haematol.2018.191429
   PubMed Web of Science ®Google Scholar
• Salles G, Gopal AK, Minnema MC, et al. Phase 2 study of daratumumab in relapsed/refractory mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19(5):275–284. doi:10.1016/j.clml.2018.12.013
   PubMed Web of Science ®Google Scholar
• Martin P, Ruan J, Furman R, et al. A Phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leuk Lymphoma. 2019;60(12):2917–2921. doi:10.1080/10428194.2019.1612062
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5(3):e109–e116. doi:10.1016/S2352-3026(18)30018-8
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Kobayashi T, Shimura Y, et al. Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-hodgkin lymphoma and mantle cell lymphoma: a multicenter Phase II study. Int J Hematol. 2019;110(1):77–85. doi:10.1007/s12185-019-02650-w
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, Phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–575. doi:10.1016/S0140-6736(16)00739-X
   PubMed Web of Science ®Google Scholar
• Tessoulin B, Bouabdallah K, Burroni B, et al. Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA. Ann Hematol. 2020;99(8):1771–1778. doi:10.1007/s00277-020-04159-3
   PubMed Web of Science ®Google Scholar
• Pulikkan JA, Viola D, Peramangalam PS, et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood. 2010;115:1768–1778. doi:10.1182/blood-2009-08-240101
   PubMed Web of Science ®Google Scholar
• Yang W, Lan X, Li D, Li T, Lu S. MiR-223 targeting MAFB suppresses proliferation and migration of nasopharyngeal carcinoma cells. BMC Cancer. 2015;15(1):461. doi:10.1186/s12885-015-1464-x
   PubMedGoogle Scholar
• Dong W, Li B, Wang J, Song Y, Zhang Z, Fu C. MicroRNA-337 inhibits cell proliferation and invasion of cervical cancer through directly targeting specificity protein 1. Tumour Biol. 2017;39(6):101042831771132. doi:10.1177/1010428317711323
   Google Scholar
• Zuo XL, Chen ZQ, Wang JF, Wang JG, Cai J. miR-337-3p suppresses the proliferation and invasion of hepatocellular carcinoma cells through targeting JAK2. Am J Cancer Res. 2018;8(4):662–674.
   PubMed Web of Science ®Google Scholar
• Yu FY, Yao HR, Zhu PC, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131:1109–1123. doi:10.1016/j.cell.2007.10.054
   PubMed Web of Science ®Google Scholar
• Pan YZ, Gao WQ, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos. 2009;37:2112–2117. doi:10.1124/dmd.109.027680
   PubMed Web of Science ®Google Scholar
• Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008;123(2):372–379. doi:10.1002/ijc.23501
   PubMed Web of Science ®Google Scholar
• Bai H, Xu R, Cao Z, Wei D, Wang C. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett. 2011;585(2):402–408. doi:10.1016/j.febslet.2010.12.027
   PubMed Web of Science ®Google Scholar
• Jeon HM, Sohn YW, Oh SY, Oh SY, Kim H. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res. 2011;71(9):3410–3421. doi:10.1158/0008-5472.CAN-10-3340
   PubMed Web of Science ®Google Scholar